Stem Pharm and Verge Genomics are teaming up to develop a 3D brain model of Parkinson’s disease that uses advanced computational tools to validate new therapeutic candidates. The collaboration will leverage Stem Pharm’s human-derived “mini-brains” that model inflammation of the brain — neuroimmune organoids — and Verge’s…
A neuroscientist at Northwestern University in Chicago was given the 2023 Annemarie Opprecht Parkinson Award, an international honor recognizing significant contributions to Parkinson’s disease research. James Surmeier, PhD, is a professor and chair of university’s neuroscience department, and a scientific advisor to the Michael J. Fox…
The mutated form of alpha-synuclein protein — a key player in the development of Parkinson’s disease — can travel in the brain to various regions using the brain’s immune system before it builds up into toxic clumps, or aggregates, a new study has found.
Homogenous cell therapy — treatments using only one cell type — may ease disease severity, lessen motor symptoms, and improve activities of daily living in people with Parkinson’s disease, according to a new systematic review. These effects were observed during patients’ off periods, times when the medication wears off…
OM1 has launched a Parkinson’s disease premium dataset to expand real-world evidence on the progression of Parkinson’s progression and its treatments. The goal is to have a comprehensive view of the course of patients’ disease and contribute to accelerating research, assessing therapies’ effectiveness, and supporting procedures to…
Serina Therapeutics will merge with a wholly-owned subsidiary of AgeX Therapeutics to advance SER-252 (POZ-apomorphine), Serina’s lead treatment candidate for advanced Parkinson’s disease. The company will continue under the Serina name and expects to submit an investigational new drug application (IND) for SER-252 to the U.S. Food…
Early results from a Phase 2 clinical trial testing lixisenatide, a medication used to treat diabetes, in people with Parkinson’s disease, indicate the treatment may slow the progression of motor symptoms. The LixiPark (NCT03439943) trial is evaluating lixisenatide’s effectiveness as add-on therapy in 156 people with early…
Gain Therapeutics’ GT-02287, an oral investigational therapy for Parkinson’s disease, was found to reduce blood levels of neurofilament light chain (NfL), a biomarker of nerve cell degeneration, in mouse models of the disorder. Further, the treatment lessened recognizable features associated with Parkinson’s symptoms — such as alpha-synuclein…
People with Parkinson’s disease can learn how to re-train their gait and improve their walking ability with the help of a new app that’s available for free on both the iOS and Android stores. Walking Tall lets users define their own training time and rhythm, and delivers a rhythmic…
RaceTrac is set to revive its “Run for Research” 5K race, scheduled for Sept. 16 at Truist Park in Atlanta, to support research for Parkinson’s disease. All proceeds, including the registration fees, will be donated to the Michael J. Fox Foundation (MJFF) research programs that seek to…
Get regular updates to your inbox.